Author:
Alqaisi Abeer,Chen Li,Romond Edward,Chambers Mara,Stevens Mark,Pasley Grace,Awasthi Mukta,Massarweh Suleiman
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Massarweh S, Schiff R (2007) Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res Off J Am Assoc Cancer Res 13(7):1950–1954. doi: 10.1158/1078-0432.CCR-06-2540
2. Dowsett M (2001) Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 8(3):191–195
3. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status, J Natl Cancer Inst 106(5). Doi: 10.1093/jnci/dju055
4. Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 11(2):865s–870s
5. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D’Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 11(13):4741–4748. doi: 10.1158/1078-0432.CCR-04-2569